CoChat

Forelimb Treatment in a Large Cohort of Dystrophic Dogs Supports Delivery of a Recombinant AAV for Exon Skipping in Duchenne Patients

Open access
Le Guiner, Caroline, Montus, Marie, Servais, Laurent, Cherel, Yan, Francois, Virginie, Thibaud, Jean-Laurent, Wary, Claire, Matot, Béatrice, Larcher, Thibaut, Guigand, Lydie, Dutilleul, Maeva, Domenger, Claire, Allais, Marine, Beuvin, Maud, Moraux, Amélie, Le Duff, Johanne, Devaux, Marie, Jaulin, Nicolas, Guilbaud, Mickaël, Latournerie, Virginie, Veron, Philippe, Boutin, Sylvie, Leborgne, Christian, Desgue, Diana, Deschamps, Jack-Yves, Moullec, Sophie, Fromes, Yves, Vulin, Adeline, Smith, Richard H, Laroudie, Nicolas, Barnay-Toutain, Frédéric, Rivière, Christel, Bucher, Stéphanie, Le, Thanh-Hoa, Delaunay, Nicolas, Gasmi, Mehdi, Kotin, Robert M, Bonne, Gisèle, Adjali, Oumeya, Masurier, Carole, Hogrel, Jean-Yves, Carlier, Pierre, Moullier, Philippe, Voit, Thomas · 2014 · Molecular Therapy
Cited by 134

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Duchenne muscular dystrophy (DMD) is a severe muscle-wasting disorder caused by mutations in the dystrophin gene, without curative treatment yet available. Our study provides, for the first time, the overall safety profile and therapeutic dose of a recombinant adeno-associated virus vector, serotype 8 (rAAV8) carrying a modified U7snRNA sequence promoting exon skipping to restore a functional in-frame dystrophin transcript, and injected by locoregional transvenous perfusion of the forelimb. Eighteen Golden Retriever Muscular Dystrophy (GRMD) dogs were exposed to increasing doses of GMP-manufactured vector. Treatment was well tolerated in all, and no acute nor delayed adverse effect, including systemic and immune toxicity was detected. There was a dose relationship for the amount of exon skipping with up to 80% of myofibers expressing dystrophin at the highest dose. Similarly, histological, nuclear magnetic resonance pathological indices and strength improvement responded in a dose-dependent manner. The systematic comparison of effects using different independent methods, allowed to define a minimum threshold of dystrophin expressing fibers (>33% for structural measures and >40% for strength) under which there was no clear-cut therapeutic effect. Altogether, these results support the concept of a phase 1/2 trial of locoregional delivery into upper limbs of nonambulatory DMD patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mt.2014.151

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 134

Metadata

Authors
Le Guiner, C., Montus, M., Servais, L., Cherel, Y., Francois, V., Thibaud, J.-L., Wary, C., Matot, B., Larcher, T., Guigand, L., Dutilleul, M., Domenger, C., Allais, M., Beuvin, M., Moraux, A., Le Duff, J., Devaux, M., Jaulin, N., Guilbaud, M., Latournerie, V., Veron, P., Boutin, S., Leborgne, C., Desgue, D., Deschamps, J.-Y., Moullec, S., Fromes, Y., Vulin, A., Smith, R. H., Laroudie, N., Barnay-Toutain, F., Rivière, C., Bucher, S., Le, T.-H., Delaunay, N., Gasmi, M., Kotin, R. M., Bonne, G., Adjali, O., Masurier, C., Hogrel, J.-Y., Carlier, P., Moullier, P., & Voit, T.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2014-11
Volume
22
Issue
11
Pages
1923-1935
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2038428739
Cited by
134
References
2
FWCI
14.07
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Forelimb Treatment in a Large Cohort of Dystrophic Dogs Supports Delivery of a Recombinant AAV for Exon Skipping in Duchenne Patients. https://app.cochat.ai/papers/10.1038/mt.2014.151
The paper
Le Guiner, C., Montus, M., Servais, L., Cherel, Y., Francois, V., Thibaud, J.-L., Wary, C., Matot, B., Larcher, T., Guigand, L., Dutilleul, M., Domenger, C., Allais, M., Beuvin, M., Moraux, A., Le Duff, J., Devaux, M., Jaulin, N., Guilbaud, M., . . . Voit, T. (2014). Forelimb Treatment in a Large Cohort of Dystrophic Dogs Supports Delivery of a Recombinant AAV for Exon Skipping in Duchenne Patients. Molecular Therapy. https://doi.org/10.1038/mt.2014.151

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.